CD47-SIRPα antagonist agents with an intact or even partially inactive Fc portion embedded in their structure may foster anti-tumor activity via antibody opsonization and destruction of target cells through ADCC or antibody-dependent cellular phagocytosis (ADCP) [45]. This evidence concerns the gene SIRPA and neoplasm.